Porphyrin-Based Organic Nanoparticles with NIR-IIa Fluorescence for Orthotopic Glioblastoma Theranostics
Source abstract
Abstract
The development of efficient theranostic nanoagents for the precise diagnosis and targeted therapy of glioblastoma (GBM) remains a big challenge. Herein, we designed and developed porphyrin-based organic nanoparticles (PNP NPs) with strong emission in the near-infrared IIa window (NIR-IIa) for orthotopic GBM theranostics. PNP NPs possess favorable photoacoustic and photothermal properties, high photostability, and low toxicity. After modification with the RGD peptide, the obtained PNPD NPs exhibited enhanced blood–brain barrier (BBB) penetration capability and GBM targeting ability. NIR-IIa imaging was employed to monitor the in vivo biodistribution and accumulation of the nanoparticles, revealing a significant enhancement in penetration depth and signal-to-noise ratio. Both in vitro and in vivo results demonstrated that PNPD NPs effectively inhibited the proliferation of tumor cells and induced negligible side effects in normal brain tissues. In general, the work presented a kind of brain-targeted porphyrin-based NPs with NIR-IIa fluorescence for orthotopic glioblastoma theranostics, showing promising prospects for clinical translation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Porphyrin and Phthalocyanine Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China
College of Health Science and Engineering, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules, Hubei University, Wuhan 430062, P. R. China
Funding
Natural Science Foundation of Hubei Province · National Natural Science Foundation of China
References (31)
Show source-provided references
1. 10.1021/acs.chemrev.1c0055310.1021/acs.chemrev.1c00553 ↗
2. 10.1039/D2CS00131D10.1039/D2CS00131D ↗
3. 10.1016/j.ccr.2023.21507010.1016/j.ccr.2023.215070 ↗
4. 10.1016/j.ccr.2018.11.00310.1016/j.ccr.2018.11.003 ↗
5. 10.1002/anie.20191439710.1002/anie.201914397 ↗
6. 10.1002/ange.20221537210.1002/ange.202215372 ↗
7. 10.1016/j.actbio.2022.10.02510.1016/j.actbio.2022.10.025 ↗
8. 10.1002/agt2.45810.1002/agt2.458 ↗
9. 10.1016/j.addr.2021.03.00810.1016/j.addr.2021.03.008 ↗
10. 10.1016/j.biomaterials.2019.11970710.1016/j.biomaterials.2019.119707 ↗
11. 10.1039/C9NR06941K10.1039/C9NR06941K ↗
12. 10.1186/s13058-021-01442-710.1186/s13058-021-01442-7 ↗
13. 10.1016/j.addr.2022.11413410.1016/j.addr.2022.114134 ↗
14. 10.1016/j.cej.2021.12884410.1016/j.cej.2021.128844 ↗
15. 10.1007/s41061-021-00348-410.1007/s41061-021-00348-4 ↗
16. 10.1002/adhm.20210252610.1002/adhm.202102526 ↗
17. 10.1016/j.mtbio.2021.10019810.1016/j.mtbio.2021.100198 ↗
18. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
19. 10.1186/s13045-022-01298-010.1186/s13045-022-01298-0 ↗
20. 10.1016/j.chempr.2017.05.00210.1016/j.chempr.2017.05.002 ↗
21. 10.1016/j.chempr.2018.06.00310.1016/j.chempr.2018.06.003 ↗
22. 10.1039/D3CS00251A10.1039/D3CS00251A ↗
23. 10.1039/C9CC09846A10.1039/C9CC09846A ↗
24. 10.1002/adfm.20210465010.1002/adfm.202104650 ↗
25. 10.1039/C4CS00436A10.1039/C4CS00436A ↗
26. 10.1016/j.nantod.2022.10155010.1016/j.nantod.2022.101550 ↗
27. 10.1002/adma.20180259110.1002/adma.201802591 ↗
28. 10.1002/advs.20200303610.1002/advs.202003036 ↗
29. 10.1002/smll.20160229310.1002/smll.201602293 ↗
30. 10.1038/s41467-020-15730-x10.1038/s41467-020-15730-x ↗
31. 10.1021/acsnano.0c0382410.1021/acsnano.0c03824 ↗